Deepak Tiwari
Career history of Deepak Tiwari
Former positions of Deepak Tiwari
| Companies | Position | Start | End |
|---|---|---|---|
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Corporate Officer/Principal | - | - |
| GLYCOMIMETICS, INC. | Chief Tech/Sci/R&D Officer | 01/03/2022 | - |
Training of Deepak Tiwari
| St. John's University | Doctorate Degree |
| University of Delhi | Undergraduate Degree |
Statistics
International
| United States | 4 |
| India | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| GLYCOMIMETICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
- Stock Market
- Insiders
- Deepak Tiwari
- Experience
